Loading clinical trials...
Loading clinical trials...
This project aims to determine the effect of significant weight loss on rates on hepatic fibrogenesis in people with obesity.
Non-alcoholic fatty liver disease (NAFLD) affects approximately 70% of those with obesity and if left untreated can progress to cirrhosis and liver failure. NAFLD stages progress from the stage of simple steatosis to steatohepatitis, and fibrosis The stage of NAFLD is currently best determined using histology from a liver biopsy, however this provides a static depiction of the state of the liver. Therefore, this project aims to determine fibrogenesis in the liver of obese humans in vivo, before and after weight loss.
Age
21 - 65 years
Sex
ALL
Healthy Volunteers
Yes
Washington University School of Medicine
St Louis, Missouri, United States
Start Date
February 1, 2019
Primary Completion Date
February 19, 2024
Completion Date
February 19, 2024
Last Updated
June 19, 2025
23
ACTUAL participants
Weight loss surgery
PROCEDURE
Lead Sponsor
Washington University School of Medicine
NCT06819917
NCT07221227
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06218589